Conditions: Opioid Use Disorder Alcohol Use Disorder
Keywords: Substance related disorders HIV naltrexone
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
The purpose of this study is to learn how best to treat substance use disorders in an HIV clinic setting. Specifically, the purpose of this pilot study is to learn if extended-release naltrexone (XR-NTX) would be a feasible and acceptable treatment for HIV-infected individuals with opioid or alcohol use disorders.

Detailed description:

Arms:
arm 1: The current standard of care for treatment of opioid use disorders in HIV clinics is opioid agonist therapy. HIV-infected patients with alcohol use disorders are typically referred for residential, outpatient, and self-help groups. arm 2: Extended release naltrexone (XR-NTX), delivered by monthly injection. Dose: 380 mg. Frequency: One injection per month, for four months. Duration: 30 days.

Interventions: intervention 1: Extended Release Naltrexone intervention 2: Treatment As usual
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: